Skip to main content
. Author manuscript; available in PMC: 2010 Mar 9.
Published in final edited form as: Biol Blood Marrow Transplant. 2008 Sep;14(9):959–972. doi: 10.1016/j.bbmt.2008.06.007

Table V.

APC Adoptive Transfer Abrogates Th2 Cell Therapy of GVHD.

Transplant Componentsb
Cohort # Host Tumora BM T cells Th2 Cells Donor DCc Host DCd Days of Post-BMT Survivale p-valuesf
1 − + − − 46(46–46)
2 + + − − 21(20–21)
3 + + + − 33(31–35) p<0.0001
(#3 vs. #2)
4 + + + − + 32(27–32) p=NS
(#4 vs. #3)
5 + + + − − + 32(27–34) p=NS
(#5 vs. #3)
6 + + + Th2 − − 45(42–46) p=0.0001
(#6 vs. #3)
7 + + + Th2 + − 34(21–36) p=NS
(#7 vs. #3)
8 + + + Th2 − + 25(18–29) p=0.02
(#8 vs. #3)
a

BALB/c host received 850 cGy XRT; 0.1×106 host TS/A tumor.

b

C57BL/6 into BALB/c (day 0); BM (C57BL/6; 10×106 cells); donor T cells (5×106 cells); donor Th2 cells (10×106 cells; day 14 post-BMT).

c

Fresh DC cells generated from donor C57BL/6 (10×106 cells; day14 post-BMT).

d

Fresh DC cells generated from host BALB/c (10×106 cells; day14 post-BMT.

e

Median and range of number of days of post-transplant survival; n=5/group.

f

Unpaired t test.